After the Cheque Clears: Bridging Britain's Grant-to-Equity Chasm

An Innovate UK grant is often treated as a finish line. It is better understood as a handover. The cheque validates a technical thesis and buys time, but it does not supply the commercial evidence that private capital expects. For UK deep-tech spinouts, the awkward period after public funding ends has become a predictable cliff: not because the science fails, but because the funding logic changes faster than the company does.

The grant is not a funding round

Public grant milestones and equity milestones are different instruments. Innovate UK funding is typically tied to project deliverables, eligible costs and consortium obligations. Investors, by contrast, underwrite a route to revenue, a defensible position in a supply chain and a management team that can sell into regulated markets. A spinout can complete every grant milestone and still be uninvestable on the metrics that matter to a lead investor. That is the gap Metis Labs hears about from founders and backers across materials, robotics and energy hardware.

The problem is compounded by language. Grant applications reward technical novelty and public-benefit framing. Equity stories reward commercial urgency and evidence of demand. When a founder presents the same roadmap to both audiences, the investor hears a research programme with a company attached. The grant has done its job, but the company has not yet been translated.

Where the handover breaks

Three failure points recur. The first is milestone mismatch. A grant might fund a prototype, a pilot line or a set of validation tests. An investor wants to know which customer will pay for the output, at what gross margin, and under which certification regime. If the grant roadmap ends at technical readiness rather than commercial proof, the next round becomes a bridge to nowhere.

The second is cap-table dilution. Match funding, convertible instruments, university equity and early grant-related arrangements can leave a spinout with a crowded register before the first institutional round. Investors are not automatically deterred by complexity, but they price it. A cap table that tells a messy story makes the lead investor's job harder and the round slower.

The third is mistrust of grant-funded roadmaps. Some investors have learned to discount grant dependency because it can mask weak commercial ownership. They ask whether the company can survive without public money, whether the grant bought a capability or merely rented one, and whether the intellectual property is cleanly assigned. These are fair questions. The answer is not to hide the grant history but to show what it proved and what it did not.

The cap table is a story, not a spreadsheet

Founders should treat the cap table as part of the investment case. A clean register, a sensible option pool and unambiguous IP assignment matter more than an elegant slide. Where university or consortium partners hold rights, the spinout needs clear, documented terms before the round begins. Investors will forgive a long grant history if the ownership story is simple. They will not forgive ambiguity once diligence starts.

A bridge built before the cliff

The practical playbook starts twelve to eighteen months before the grant ends. Founders should translate technical milestones into commercial evidence: letters of intent, paid pilots, procurement conversations, certification pathways and a bottom-up route to revenue. The grant should be used to buy customer access as well as technical certainty. A project that ends with a working prototype and no customer conversation has underused its public funding.

Backers can help by treating the grant as a stage, not a verdict. Angel syndicates, family offices and corporate venture arms are often better suited than generalist funds to bridge a deep-tech spinout through a short commercial gap. Specialist deep-tech funds can then lead the larger round once the evidence exists. The instrument matters less than the sequence: small, staged capital tied to commercial proof is usually more useful than one large cheque that arrives too late.

What backers should ask

Investors should separate grant dependency from grant validation. Ask what the grant bought, what remains proprietary, who owns the background IP and what the company can sell without further public support. Ask whether the management team has a commercial owner, not just a principal investigator. Ask which customer segment has already shown willingness to pay, even if only through a pilot. These questions turn a grant history from a red flag into a due-diligence input.

For founders, the discipline is to stop presenting the grant as the achievement. The achievement is the commercial capability that survives after the cheque clears. Britain's deep-tech base is strong enough to produce more of those capabilities. The missing layer is a handover that private capital can underwrite with confidence.